Cargando…

Coumaphos Exposure and Incident Cancer among Male Participants in the Agricultural Health Study (AHS)

BACKGROUND: Coumaphos is an organophosphate livestock insecticide. Previous research in the Agricultural Health Study (AHS) cohort observed a positive association between coumaphos and prostate cancer in men with a family history of prostate cancer. OBJECTIVES: This study was performed to determine...

Descripción completa

Detalles Bibliográficos
Autores principales: Christensen, Carol H., Platz, Elizabeth A., Andreotti, Gabriella, Blair, Aaron, Hoppin, Jane A., Koutros, Stella, Lynch, Charles F., Sandler, Dale P., Alavanja, Michael C.R.
Formato: Texto
Lenguaje:English
Publicado: National Institute of Environmental Health Sciences 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2831974/
https://www.ncbi.nlm.nih.gov/pubmed/20056581
http://dx.doi.org/10.1289/ehp.0800446
Descripción
Sumario:BACKGROUND: Coumaphos is an organophosphate livestock insecticide. Previous research in the Agricultural Health Study (AHS) cohort observed a positive association between coumaphos and prostate cancer in men with a family history of prostate cancer. OBJECTIVES: This study was performed to determine the association between coumaphos and other major cancer sites and to explore the consistency of the association with prostate cancer early (1993–1999) and later (2000–2005) in AHS follow-up. METHODS: This study included 47,822 male licensed pesticide applicators. Incident cases were ascertained by linkage to state cancer registries, and exposure data were collected by enrollment questionnaire. Poisson regression was used to estimate rate ratio (RR) and 95% confidence interval (CI) of cancer for coumaphos exposure controlling for potentially confounding variables. RESULTS: Approximately 8% of applicators reported use of coumaphos; 8.5% reported a family history of prostate cancer. Cumulative exposure to coumaphos was not associated with cancer risk overall or with any major cancer site including prostate. In men with a family history of prostate cancer, we observed a positive association between ever use of coumaphos and prostate cancer in both early (RR = 2.07; 95% CI, 1.19–3.62, p-interaction = 0.005) and later (RR = 1.46; 95% CI, 0.89–2.40; p-interaction = 0.11) periods of follow-up. Across all years, this association was statistically significant (RR = 1.65; 95% CI, 1.13–2.38; p-interaction = 0.004). CONCLUSION: Coumaphos was not associated with any cancer evaluated here. In men with a family history of disease, there was evidence of an association between coumaphos and prostate cancer, possibly due to genetic susceptibility; however, other explanations, including chance, are plausible.